Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Olema Pharmaceuticals, Inc.OLMA · Entity 613 | Director | June 18, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Olema Pharmaceuticals, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.51 · Expires 2036-06-18 | Direct | 29,500 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 29,500 · Balance 29,500 F1: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 23, 2026 21:22 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (right to buy) · Derivative | 29,500 | $0.00 Strike: $9.51 | $0.00 |
DisclosureSEC source: 0001162157-26-000002 · form4-06232026_090631.xml · derivative · entry 1 RAPPAPORT ANDREW · CIK 0001162157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,500 Underlying: Common Stock · 29,500 shares Expires 2036-06-18 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| November 25, 2025 Filed Nov 25, 2025 23:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GiftCommon Stock | 35,868 | $0.00 | $0.00 |
DisclosureSEC source: 0001162157-25-000005 · form4-11252025_061101.xml · nonDerivative · entry 2 RAPPAPORT ANDREW · CIK 0001162157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The reporting person transferred 35,868 to the Rappaport Family Foundation, a charitable foundation of which the reporting person is an officer, as a bona fide gift for no consideration. The reporting person has voting and dispositive power over all securities owned by the foundation. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 23:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionStock Option (right to buy) · Derivative | 35,868 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001162157-25-000005 · form4-11252025_061101.xml · derivative · entry 4 RAPPAPORT ANDREW · CIK 0001162157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,868 shares Expires 2025-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 23:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | Exercise / conversionCommon Stock | 35,868 | $0.39 | $13,988.52 |
DisclosureSEC source: 0001162157-25-000005 · form4-11252025_061101.xml · nonDerivative · entry 1 RAPPAPORT ANDREW · CIK 0001162157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 21:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (right to buy) · Derivative | 24,150 | $0.00 Strike: $4.08 | $0.00 |
DisclosureSEC source: 0001415889-25-017232 · form4-06132025_050610.xml · derivative · entry 1 RAPPAPORT ANDREW · CIK 0001162157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,150 Underlying: Common Stock · 24,150 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 21:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (right to buy) · Derivative | 23,000 | $0.00 Strike: $12.36 | $0.00 |
DisclosureSEC source: 0001415889-24-017447 · form4-06182024_050618.xml · derivative · entry 1 RAPPAPORT ANDREW · CIK 0001162157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2034-06-14 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| March 05, 2024 Filed Mar 6, 2024 22:36 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | OtherCommon Stock | 385,965 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007081 · form4-03062024_100356.xml · nonDerivative · entry 2 RAPPAPORT ANDREW · CIK 0001162157 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 385,965 F1 · kind: Pro rata distribution for no consideration from SPW Investments LLC ("SPWI") to its members. Skyline Public Works, LLC, of which the Reporting Person is a managing member, is the general partner of SPWI. F3 · ownership.nature: The shares are held by the Rappaport Family Trust, of which the reporting person is co-trustee. Read SEC document |
| March 05, 2024 Filed Mar 6, 2024 22:36 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | OtherCommon Stock | 481,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007081 · form4-03062024_100356.xml · nonDerivative · entry 1 RAPPAPORT ANDREW · CIK 0001162157 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: Pro rata distribution for no consideration from SPW Investments LLC ("SPWI") to its members. Skyline Public Works, LLC, of which the Reporting Person is a managing member, is the general partner of SPWI. F2 · ownership.nature: The shares were held by SPWI. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 21:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (right to buy) · Derivative | 21,520 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0001415889-23-010100 · form4-06212023_050601.xml · derivative · entry 1 RAPPAPORT ANDREW · CIK 0001162157 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,520 Underlying: Common Stock · 21,520 shares Expires 2033-06-15 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 17, 2022 Filed Jun 27, 2022 21:06 UTC Amendment | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (right to buy) · Derivative | 21,520 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001415889-22-006959 · form4a-06272022_020613.xml · derivative · entry 1 RAPPAPORT ANDREW · CIK 0001162157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,520 Underlying: Common Stock · 21,520 shares Expires 2032-06-16 F1 · derivative.exercise_price: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein. F1 · date: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein. F2 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 17, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 23:27 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (right to buy) · Derivative | 21,520 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001415889-22-006783 · form4-06172022_040617.xml · derivative · entry 1 RAPPAPORT ANDREW · CIK 0001162157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,520 Underlying: Common Stock · 21,520 shares Expires 2032-06-15 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 22:35 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (right to buy) · Derivative | 21,520 | $0.00 Strike: $27.66 | $0.00 |
DisclosureSEC source: 0001415889-21-002923 · form4-06102021_030600.xml · derivative · entry 1 RAPPAPORT ANDREW · CIK 0001162157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,520 Underlying: Common Stock · 21,520 shares Expires 2031-06-08 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 9, 2021, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 21:35 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionSeries A-1 Convertible Preferred Stock · Derivative | 129,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-059978 · doc4.xml · derivative · entry 4 RAPPAPORT ANDREW · CIK 0001162157 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 129,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · price: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. F2 · ownership.nature: The shares are held by SPW Investments LLC ("SPWI"). Skyline Public Works, LLC, of which the Reporting Person is a managing member, is the general partner of SPWI. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 21:35 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionSeries A Convertible Preferred Stock · Derivative | 318,723 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-059978 · doc4.xml · derivative · entry 3 RAPPAPORT ANDREW · CIK 0001162157 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 318,723 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · price: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. F2 · ownership.nature: The shares are held by SPW Investments LLC ("SPWI"). Skyline Public Works, LLC, of which the Reporting Person is a managing member, is the general partner of SPWI. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 21:35 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionCommon Stock | 129,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-059978 · doc4.xml · nonDerivative · entry 2 RAPPAPORT ANDREW · CIK 0001162157 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 481,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. F2 · ownership.nature: The shares are held by SPW Investments LLC ("SPWI"). Skyline Public Works, LLC, of which the Reporting Person is a managing member, is the general partner of SPWI. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 21:35 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionCommon Stock | 318,723 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-059978 · doc4.xml · nonDerivative · entry 1 RAPPAPORT ANDREW · CIK 0001162157 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 351,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. F2 · ownership.nature: The shares are held by SPW Investments LLC ("SPWI"). Skyline Public Works, LLC, of which the Reporting Person is a managing member, is the general partner of SPWI. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 00:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 21,520 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059526 · doc4.xml · derivative · entry 2 RAPPAPORT ANDREW · CIK 0001162157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,520 Underlying: Common Stock · 21,520 shares Expires 2030-11-17 F2 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthy installments measured from June 1, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 18, 2020 Filed Nov 20, 2020 00:00 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 56,964 | $0.00 Strike: $4.82 | $0.00 |
DisclosureSEC source: 0001209191-20-059526 · doc4.xml · derivative · entry 1 RAPPAPORT ANDREW · CIK 0001162157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,964 Underlying: Common Stock · 56,964 shares Expires 2030-09-17 F1 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.